Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-HIF2 in advanced clear cell renal cell carcinoma
NCT04169711Phase 1Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Aug 2020
- Primary completion
- Jan 2022
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zifcasiran in clear cell renal cell carcinoma (ccRCC), sponsored by Arrowhead Pharmaceuticals. Primary endpoint: Adverse Events Possibly or Probably Related to Treatment up to 2 years. Started Aug 2020; status: completed.
02
Drugs
zifcasiran
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04169711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04169711.